aromasil has been researched along with Bone Fractures in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V | 1 |
| Banks, LM; Bliss, JM; Cawthorn, SJ; Coleman, RE; Coombes, RC; Fox, J; Girgis, SI; Kilburn, LS; Patel, A; Vrdoljak, E | 1 |
| Becker, M; Bossart, M; Hadji, P; Hasenburg, A; Kieback, DG | 1 |
| Tanvetyanon, T | 1 |
| Chien, AJ; Goss, PE | 1 |
| Banks, LM; Bliss, JM; Cawthorn, SJ; Coleman, RE; Coombes, RC; Fox, J; Girgis, SI; Hall, E; Kilburn, LS; Patel, A; Snowdon, CF; Vrdoljak, E | 1 |
1 review(s) available for aromasil and Bone Fractures
| Article | Year |
|---|---|
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles | 2006 |
4 trial(s) available for aromasil and Bone Fractures
| Article | Year |
|---|---|
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bones of Lower Extremity; Breast Neoplasms; Calcium; Canada; Chemotherapy, Adjuvant; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Time Factors; Treatment Outcome; Triazoles; United States; Vitamin D | 2014 |
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Topics: Absorptiometry, Photon; Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Australia; Biomarkers; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Estrogen Antagonists; Europe; Female; Fractures, Bone; Humans; Middle Aged; Odds Ratio; Risk Assessment; Risk Factors; Tamoxifen; Time Factors; United States | 2010 |
Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.
Topics: Analgesics; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Interactions; Female; Fractures, Bone; Humans; Medication Adherence; Middle Aged; Retrospective Studies; Tamoxifen | 2012 |
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Topics: Androstadienes; Antineoplastic Agents; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Hip; Humans; Incidence; Lumbar Vertebrae; Postmenopause; Radiography; Risk Factors; Spine; Tamoxifen; Time Factors; Treatment Outcome | 2007 |
1 other study(ies) available for aromasil and Bone Fractures
| Article | Year |
|---|---|
Adjuvant treatment of breast cancer with exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Osteoporosis; Tamoxifen | 2004 |